登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由天津医科大学肿瘤医院牵头,本站收录的另外 4 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 5
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 牵头方天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
- 研究中心河南科技大学第一附属医院First Affiliated Hospital of Henan University of Science and Technology洛阳医院页面
- 研究中心中山大学附属第一医院First Affiliated Hospital of Sun Yat-sen University广州医院页面
- 研究中心河北医科大学第四医院Fourth Hospital of Hebei Medical University石家庄医院页面
- 研究中心广东省人民医院Guangdong Provincial People's Hospital广州医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07246317,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 70 岁;性别:仅女性
登记记录的入选字段
Histologically/cytologically confirmed primary breast cancer.
入选标准第 4 条
AJCC 8th edition Stage II-IIIC (T2-T4 any N, or any T N1-3 M0) unilateral invasive breast cancer.
入选标准第 6 条
Other malignancies within 3 years, except: those treated with surgery alone and disease-free for 5 years; cured cervical carcinoma in situ, non-melanoma skin cancer, or superficial bladder cancer [Ta, Tis, T1].
排除标准第 3 条
Myocardial ischemia/infarction (≥Grade 2), arrhythmias (QTc≥450ms M, ≥470ms F), or CHF (≥NYHA Class II).
排除标准第 13 条
For women of childbearing potential: negative pregnancy test within 7 days prior to treatment; must not be breastfeeding.
入选标准第 16 条
Use of highly effective contraception during and for 3 months after treatment.
入选标准第 17 条
Prior anti-tumor therapy (chemotherapy, endocrine, anti-HER2) or breast surgery for breast cancer within 3 years (excluding diagnostic biopsy).
排除标准第 4 条
Use of Chinese patent medicines with approved anti-tumor indications within 2 weeks prior to treatment.
排除标准第 16 条
ECOG PS 0-1; life expectancy >6 months.
入选标准第 3 条
ANC ≥1.5×10⁹/L; PLT ≥100×10⁹/L; HGB ≥90 g/L
入选标准第 12 条
Creatinine ≤1.5×ULN
入选标准第 14 条
PT/APTT/INR ≤1.5×ULN (or within therapeutic range if on anticoagulants)
入选标准第 15 条
Active infection, unexplained fever ≥38.5°C within 7 days, or baseline WBC >15×10⁹/L.
排除标准第 24 条
At least one measurable lesion per RECIST 1.1.
入选标准第 8 条
Active HCV (RNA+), HIV+, syphilis (unless cured), or HBV (HBsAg+ with HBV DNA≥2000 IU/ml or positive qualitative test).
排除标准第 15 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07246317,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Signed informed consent and compliant. Age 18-70 years. ECOG PS 0-1; life expectancy >6 months. Histologically/cytologically confirmed primary breast cancer. Primary tumor >2cm (by local standard assessment) or node-positive disease. AJCC 8th edition Stage II-IIIC (T2-T4 any N, or any T N1-3 M0) unilateral invasive breast cancer. Confirmed HER2-positive (IHC 3+ or ISH positive). Note: Patients with HER2-negative primary tumor but HER2-positive nodes are eligible. At least one measurable lesion per RECIST 1.1. Agreement to undergo surgery if indicated after neoadjuvant therapy. Willing to provide tumor tissue for biomarker analysis. Adequate organ function: ANC ≥1.5×10⁹/L; PLT ≥100×10⁹/L; HGB ≥90 g/L Albumin ≥30 g/L Creatinine ≤1.5×ULN PT/APTT/INR ≤1.5×ULN (or within therapeutic range if on anticoagulants) For women of childbearing potential: negative pregnancy test within 7 days prior to treatment; must not be breastfeeding. Use of highly effective contraception during and for 3 months after treatment.排除标准:Exclusion Criteria:
Stage IV metastatic breast cancer or patients deemed ineligible for curative surgery after neoadjuvant therapy. Inflammatory breast cancer. Other malignancies within 3 years, except: those treated with surgery alone and disease-free for 5 years; cured cervical carcinoma in situ, non-melanoma skin cancer, or superficial bladder cancer [Ta, Tis, T1]. Prior anti-tumor therapy (chemotherapy, endocrine, anti-HER2) or breast surgery for breast cancer within 3 years (excluding diagnostic biopsy). Major surgery or significant traumatic injury within 28 days before treatment (excluding diagnostic biopsy). Active or history of autoimmune diseases (e.g., autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism). Exceptions: vitiligo, childhood asthma in complete remission without intervention in adulthood. Current use of immunosuppressants or systemic corticosteroids (>10mg/day prednisone equivalent) within 2 weeks prior to enrollment. History of severe hypersensitivity to monoclonal antibodies. Known central nervous system metastases. Poorly controlled concurrent illnesses, including: Uncontrolled hypertension (SBP>150 or DBP>100 mmHg on medication) or history of hypertensive crisis/encephalopathy. History of heart failure or systolic dysfunction (LVEF <55%). Myocardial ischemia/infarction (≥Grade 2), arrhythmias (QTc≥450ms M, ≥470ms F), or CHF (≥NYHA Class II). Angina requiring medication; clinically significant valvular disease. Active HCV (RNA+), HIV+, syphilis (unless cured), or HBV (HBsAg+ with HBV DNA≥2000 IU/ml or positive qualitative test). Use of Chinese patent medicines with approved anti-tumor indications within 2 weeks prior to treatment. Significant bleeding tendency or clinical bleeding within 3 months; positive fecal occult blood requiring gastroscopy if persistently positive. Tumor invasion or high risk of invasion into major vessels, potentially causing fatal hemorrhage. Pleural, peritoneal, or pericardial effusion requiring drainage (eligible if stable after drainage). Arterial/venous thromboembolic events within 6 months (e.g., CVA, TIA, DVT, PE). Known hereditary or acquired bleeding/thrombotic tendencies (e.g., hemophilia). Severe, non-healing wounds, active ulcers, or untreated fractures. Urinary protein ≥++ confirmed by 24-hour urine protein >1.0g. Active infection, unexplained fever ≥38.5°C within 7 days, or baseline WBC >15×10⁹/L. History of drug abuse or psychiatric disorders. Participation in other anti-tumor drug trials within 4 weeks. Allergy to any study drug or its components. Any condition deemed by the investigator to pose a safety risk or affect study completion.
引自 ClinicalTrials.gov, NCT07246317, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07246317,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。